Transcode Therapeutics, Inc. (Transcode) (Nasdaq: RNAZ), an emerging RNA oncology firm built on the idea that most cancers can be defeated through clever design and efficient supply of RNA therapeutics, has just introduced Zadravka. Medarova, Ph.D. Appointed as Chief Specialization Officer of the Corporate on 1st October, 2021. Dr. Medarova is a scientific co-founder of Transcode and has served as a member of Transcode’s advisory board since its founding in January 2016.
“We are delighted to welcome Zadravka as a full-time member of the Transcode staff,” said Transcode CEO Michael Dudley. In addition to their help with our preclinical analysis through affiliation with Harvard Medical Faculty and Massachusetts Normal Hospital, we now benefit from deep experience developing nanotechnology and imaging devices to better understand cancer initiation and development Is.
Managing Zdravka will be invaluable as we follow the validation of our TTX platform as a viable means to deliver on the promise of RNA therapeutics for the treatment of most cancers. ”
Dr. Medarova joined Transcode from the Harvard Medical Faculty and Massachusetts Normal Hospital (MGH), where she was Associate Professor of Radiology at Harvard Medical Faculty and Athinoula A. Worked as an assistant in neuroimaging at Martinos Heart for Biomedical Imaging. Dr. Medarova did seminal work in the field of RNA oncology.
Collectively with their colleagues at MGH, they described, for the first time, the design and utility of iron oxide nanoparticles as an imaging-enabled carrier of siRNA for tumors. This work generated considerable curiosity in the analysis neighborhood as it illustrated the value of those nanoparticles for delivering small RNA treatments for oncology purposes and described a strategy for noninvasive monitoring of RNA supply.
Since then, Dr. Medarova has emerged as one of several leaders within the discipline of non-coding RNA supply for most cancers. She has developed a strong NIH funded program and authored several high-impact publications on the topics of RNA supply, nanotechnology, and the biology of most cancer metastases.
Dr. Medrova has done B.A. in Pre-Medicine from the College of Southern Maine and a Ph.D. in genetics from New Hampshire College.
“As one of all of Transcode’s scientific co-founders, as well as supporting corporate as a researcher and consultant, I have done significant publicity for the corporate’s TTX supply platform and lead candidate, the TTX-MC138,” Dr. Medarova said. “Throughout this expertise, I think TRANCODE’s strategy can eventually solve the persistent problem of RNA supply in oncology with the potential for super affected individual effects.
I am working to add TRANCODE at this essential time within the firm’s progress. I am looking forward to this, with the first human research and medical evaluation on the horizon, to help transcode the knowledge to reach its full potential.”
Dr. Medarova is currently invited to the upcoming Worldwide Oligonucleotide and Peptide Convention (IOPC) on October 18-19, 2021. Their discussion, “The Way Forward to Oncology Through the Lens of RNA”, will help with the strategy of transcode to RNA supply. is using its TTX platform technology.
About Transcode Therapeutics
Transcode is an emerging RNA oncology firm built on the idea that most cancers can be defeated through clever design and efficient supply of RNA therapeutics. The firm has created a platform for drug candidates, designed to focus on multiple varieties of tumors, with the goal of significantly increasing patient outcomes.
The firm’s lead therapeutic candidate, TTX-MC138, is focused on treating most metastatic cancers, which cause approximately 90% of all cancer deaths worldwide, representing more than 9 million deaths per 12 months. Is. The firm believes that TTX-MC138 has the potential to supply regression without recurrence in a variety of cancers, including most cancers of the breast, pancreatic, ovarian and colon, glioblastoma and others.
The firm’s various drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on tumor treatment by focusing on PD-L1 and Lin28b, respectively. The firm is also expanding its diagnostic merchandise associated with its intentional medical business.
This launch includes “forward-looking statements” within that medium of the Personal Securities Litigation Reform Act of 1995, as well as, without limitation, statements regarding the therapeutic potential of TTX-MC138 and Transcode’s Growth Package and TTX Technology. Contains statements about. platform generally.
Any forward-looking statements at this press launch are based mostly on the Administration’s current expectations of future opportunities and are subject to a number of risks and uncertainties that could cause accurate results to differ materially and unfavorably.